Maurizio Osio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maurizio Osio has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Caterina Nascimbene
U.O. Neurologia, Ospedale Luigi Sacco
2 shared publicationsClaudio Mariani
U.O. Neurologia, Ospedale Luigi Sacco
2 shared publicationsEnrico Mailland
U.O. Neurologia, Ospedale Luigi Sacco
2 shared publicationsAlessandra Vanotti
U.O. Neurologia, Ospedale Luigi Sacco, Milan, Italy
1 shared publicationAntonietta Cargnel
Department of Infectious Diseases, Ospedale Luigi Sacco, Milano, Italy
1 shared publicationElisa Capiluppi
U.O. Neurologia, Ospedale Luigi Sacco
1 shared publication
Latest Publications
- 1 January 2007
- Published by Springer Nature in CNS Drugs
- Vol. 21 (Supplement) , 3-12
Overview on Pathophysiology and Newer Approaches to Treatment of Peripheral Neuropathies
Peripheral neuropathies are extremely heterogeneous nosological entities. One of the most common symptoms is pain, the underlying mechanisms of which are numerous and complex. Inflammation,...
- 1 January 2007
- Published by Springer Nature in CNS Drugs
- Vol. 21 (Supplement) , 3-12
Overview on Pathophysiology and Newer Approaches to Treatment of Peripheral Neuropathies
Peripheral neuropathies are extremely heterogeneous nosological entities. One of the most common symptoms is pain, the underlying mechanisms of which are numerous and complex. Inflammation,...
- 7 March 2006
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 11 (1) , 72-76
Acetyl‐l‐carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study
Antiretroviral toxic neuropathy causes morbidity in human immunodeficiency virus (HIV) patients under dideoxynucleoside therapy, benefits only partially from medical therapy, and often leads to drug discontinuation. Proposed pathogeneses include a disorder of mitochondrial oxidative metabolism, eventually related to a reduction of mitochondrial DNA content, and interference with nerve growth factor activity. Carnitine is a substrate of energy production reactions in mitochondria and is involved in many anabolic reactions. Acetyl carnitine treatment promotes peripheral nerve regeneration and has neuroprotective properties and a direct analgesic role related to glutamatergic and cholinergic modulation. The aim of this study was to evaluate acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in HIV patients. Twenty subjects affected by painful antiretroviral toxic neuropathy were treated with oral acetyl-l-carnitine at a dose of 2,000 mg/day for a 4-week period. Efficacy was evaluated by means of the modified Short Form McGill Pain Questionnaire with each item rated on an 11-point intensity scale at weekly intervals and by electromyography at baseline and final visit. Mean pain intensity score was significantly reduced during the study, changing from 7.35 +/- 1.98 (mean +/- SD) at baseline to 5.80 +/- 2.63 at week 4 (p = 0.0001). Electrophysiological parameters did not significantly change between baseline and week 4. In this study, acetyl-l-carnitine was effective and well tolerated in symptomatic treatment of painful neuropathy associated with antiretroviral toxicity. On the contrary, no effect was noted on neurophysiological parameters.
- 7 March 2006
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 11 (1) , 72-76
Acetyl‐l‐carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study
Antiretroviral toxic neuropathy causes morbidity in human immunodeficiency virus (HIV) patients under dideoxynucleoside therapy, benefits only partially from medical therapy, and often leads to drug discontinuation. Proposed pathogeneses include a disorder of mitochondrial oxidative metabolism, eventually related to a reduction of mitochondrial DNA content, and interference with nerve growth factor activity. Carnitine is a substrate of energy production reactions in mitochondria and is involved in many anabolic reactions. Acetyl carnitine treatment promotes peripheral nerve regeneration and has neuroprotective properties and a direct analgesic role related to glutamatergic and cholinergic modulation. The aim of this study was to evaluate acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in HIV patients. Twenty subjects affected by painful antiretroviral toxic neuropathy were treated with oral acetyl-l-carnitine at a dose of 2,000 mg/day for a 4-week period. Efficacy was evaluated by means of the modified Short Form McGill Pain Questionnaire with each item rated on an 11-point intensity scale at weekly intervals and by electromyography at baseline and final visit. Mean pain intensity score was significantly reduced during the study, changing from 7.35 +/- 1.98 (mean +/- SD) at baseline to 5.80 +/- 2.63 at week 4 (p = 0.0001). Electrophysiological parameters did not significantly change between baseline and week 4. In this study, acetyl-l-carnitine was effective and well tolerated in symptomatic treatment of painful neuropathy associated with antiretroviral toxicity. On the contrary, no effect was noted on neurophysiological parameters.